569 related articles for article (PubMed ID: 24910934)
1. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
Magid M; Reichenberg JS; Poth PE; Robertson HT; LaViolette AK; Kruger TH; Wollmer MA
J Clin Psychiatry; 2014 Aug; 75(8):837-44. PubMed ID: 24910934
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
3. Facing depression with botulinum toxin: a randomized controlled trial.
Wollmer MA; de Boer C; Kalak N; Beck J; Götz T; Schmidt T; Hodzic M; Bayer U; Kollmann T; Kollewe K; Sönmez D; Duntsch K; Haug MD; Schedlowski M; Hatzinger M; Dressler D; Brand S; Holsboer-Trachsler E; Kruger TH
J Psychiatr Res; 2012 May; 46(5):574-81. PubMed ID: 22364892
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
6. Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials.
Magid M; Finzi E; Kruger TH; Robertson HT; Keeling BH; Jung S; Reichenberg JS; Rosenthal NE; Wollmer MA
Pharmacopsychiatry; 2015 Sep; 48(6):205-10. PubMed ID: 26252721
[TBL] [Abstract][Full Text] [Related]
7. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
8. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
9. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
[TBL] [Abstract][Full Text] [Related]
10. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial.
Finzi E; Rosenthal NE
J Psychiatr Res; 2014 May; 52():1-6. PubMed ID: 24345483
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
[TBL] [Abstract][Full Text] [Related]
14. Topical diltiazem cream versus botulinum toxin a for the treatment of chronic anal fissure: a double-blind randomized clinical trial.
Samim M; Twigt B; Stoker L; Pronk A
Ann Surg; 2012 Jan; 255(1):18-22. PubMed ID: 21685792
[TBL] [Abstract][Full Text] [Related]
15. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
17. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
20. Comparison of venlafaxine alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder.
Güzel Özdemir P; Boysan M; Smolensky MH; Selvi Y; Aydin A; Yilmaz E
J Clin Psychiatry; 2015 May; 76(5):e645-54. PubMed ID: 26035199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
